share_log

Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53

Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53

奧本海默以跑贏大盤的評級開始對Kymera Therapeutics進行報道,宣佈目標股價爲53美元
Moomoo 24/7 ·  04/22 07:28

Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $53.

奧本海默分析師傑夫·瓊斯開始對Kymera Therapeutics(納斯達克股票代碼:KYMR)進行報道,評級爲跑贏大盤,並宣佈目標股價爲53美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論